Stock listing
Stockholm:EXPRS2 ExpreS2ion Biotech Holding AB Aktie
Home listing (Stockholm) of ExpreS2ion Biotech Holding AB
Follow ExpreS2ion Biotech Holding AB into a list and get an email when it puts out news.
Share price · OMXSTO:EXPRS2
0.82 SEK -0.13 (-13.7%)
Close on Nov 20, 2026
- Day range
- 0.61 – 1.00 SEKNov 20, 2026
- Volume
- 279,511 sharesNov 20, 2026
- Market cap
- 8.10M SEKAt the close on Nov 20, 2026 · price × 9.88M shares outstanding
- 52-week range
- 0.61 – 6.63 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 116,500 SEKMedian day 63,977 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:EXPRS2 · Home | 0.82 SEK | -0.13 (-13.7%) | 279,511 | 1.00 | 1.00 | 0.61 | 0.95 | Close on Nov 20, 2026 |
| Frankfurt:5JD0 | €0.043 EUR | -0.012 (-21.8%) | — | €0.055 | €0.055 | €0.043 | €0.055 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:EXPRS2 · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.82 | -0.13 | -13.7% | 1.00 | 1.00 | 0.61 | 279,511 | |
| 0.95 | -0.048 | -4.8% | 1.005 | 1.005 | 0.93 | 101,249 | |
| 0.998 | +0.058 | +6.2% | 0.966 | 1.04 | 0.966 | 163,056 | |
| 0.94 | -0.05 | -5.1% | 0.99 | 0.99 | 0.932 | 55,947 | |
| 0.99 | +0.03 | +3.1% | 0.97 | 1.00 | 0.914 | 152,416 | |
| 0.96 | -0.03 | -3.0% | 0.914 | 1.00 | 0.902 | 24,596 | |
| 0.99 | +0.062 | +6.7% | 1.01 | 1.01 | 0.914 | 12,659 | |
| 0.928 | -0.072 | -7.2% | 0.98 | 1.05 | 0.90 | 116,018 | |
| 1.00 | 0.00 | 0.0% | 1.025 | 1.06 | 0.976 | 123,999 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.01 | 0.94 | 40,047 | |
| 1.00 | +0.008 | +0.8% | 0.99 | 1.00 | 0.93 | 49,682 | |
| 0.992 | +0.058 | +6.2% | 0.936 | 1.00 | 0.90 | 64,529 | |
| 0.934 | 0.00 | 0.0% | 0.934 | 0.95 | 0.934 | 36,006 | |
| 0.934 | -0.096 | -9.3% | 0.998 | 1.01 | 0.934 | 117,309 | |
| 1.03 | -0.01 | -1.0% | 1.04 | 1.04 | 0.96 | 20,299 | |
| 1.04 | +0.05 | +5.1% | 1.00 | 1.045 | 0.928 | 77,809 | |
| 0.99 | -0.06 | -5.7% | 1.05 | 1.05 | 0.90 | 307,308 | |
| 1.05 | -0.03 | -2.8% | 1.015 | 1.105 | 0.98 | 264,441 | |
| 1.08 | +0.02 | +1.9% | 0.978 | 1.08 | 0.968 | 46,533 | |
| 1.06 | 0.00 | 0.0% | 1.06 | 1.07 | 0.968 | 16,809 | |
| 1.06 | +0.04 | +3.9% | 1.00 | 1.06 | 1.00 | 28,020 | |
| 1.02 | -0.01 | -1.0% | 0.966 | 1.045 | 0.956 | 26,676 | |
| 1.03 | 0.00 | 0.0% | 0.98 | 1.06 | 0.966 | 30,117 | |
| 1.03 | 0.00 | 0.0% | 0.902 | 1.03 | 0.88 | 292,957 | |
| 1.03 | -0.06 | -5.5% | 1.09 | 1.09 | 0.914 | 146,931 | |
| 1.09 | +0.01 | +0.9% | 1.095 | 1.095 | 1.03 | 74,702 | |
| 1.08 | -0.01 | -0.9% | 1.09 | 1.14 | 1.02 | 78,301 | |
| 1.09 | +0.035 | +3.3% | 1.04 | 1.15 | 1.04 | 65,645 | |
| 1.055 | -0.005 | -0.5% | 1.06 | 1.06 | 0.982 | 53,473 | |
| 1.06 | -0.065 | -5.8% | 1.125 | 1.125 | 1.04 | 29,230 | |
| 1.125 | +0.005 | +0.4% | 1.13 | 1.13 | 1.09 | 85,393 | |
| 1.12 | +0.025 | +2.3% | 1.12 | 1.125 | 1.08 | 53,873 | |
| 1.095 | -0.07 | -6.0% | 1.105 | 1.15 | 1.08 | 162,264 | |
| 1.165 | -0.025 | -2.1% | 1.195 | 1.195 | 1.135 | 37,655 | |
| 1.19 | +0.025 | +2.1% | 1.165 | 1.20 | 1.09 | 140,322 | |
| 1.165 | +0.05 | +4.5% | 1.08 | 1.165 | 1.07 | 50,192 | |
| 1.115 | -0.015 | -1.3% | 1.13 | 1.135 | 1.085 | 37,111 | |
| 1.13 | +0.005 | +0.4% | 1.115 | 1.15 | 1.08 | 41,912 | |
| 1.125 | -0.055 | -4.7% | 1.17 | 1.17 | 1.04 | 73,211 | |
| 1.18 | -0.025 | -2.1% | 1.205 | 1.235 | 1.18 | 40,671 | |
| 1.205 | -0.025 | -2.0% | 1.235 | 1.235 | 1.195 | 72,526 | |
| 1.23 | -0.09 | -6.8% | 1.32 | 1.32 | 1.21 | 70,631 | |
| 1.32 | +0.02 | +1.5% | 1.30 | 1.32 | 1.24 | 39,187 | |
| 1.30 | -0.03 | -2.3% | 1.225 | 1.325 | 1.225 | 28,716 | |
| 1.33 | +0.005 | +0.4% | 1.345 | 1.39 | 1.275 | 63,425 | |
| 1.325 | +0.075 | +6.0% | 1.295 | 1.40 | 1.29 | 201,136 | |
| 1.25 | 0.00 | 0.0% | 1.25 | 1.30 | 1.205 | 33,844 | |
| 1.25 | -0.005 | -0.4% | 1.215 | 1.355 | 1.215 | 22,555 | |
| 1.255 | -0.03 | -2.3% | 1.285 | 1.285 | 1.205 | 74,080 | |
| 1.285 | -0.065 | -4.8% | 1.305 | 1.325 | 1.285 | 15,547 | |
| 1.35 | 0.00 | 0.0% | 1.29 | 1.37 | 1.29 | 54,480 | |
| 1.35 | +0.005 | +0.4% | 1.37 | 1.37 | 1.285 | 35,265 | |
| 1.345 | -0.05 | -3.6% | 1.32 | 1.375 | 1.29 | 47,307 | |
| 1.395 | +0.065 | +4.9% | 1.33 | 1.40 | 1.25 | 158,636 | |
| 1.33 | -0.085 | -6.0% | 1.325 | 1.41 | 1.27 | 33,613 | |
| 1.415 | +0.11 | +8.4% | 1.30 | 1.415 | 1.255 | 76,290 | |
| 1.305 | +0.005 | +0.4% | 1.30 | 1.31 | 1.235 | 87,583 | |
| 1.30 | +0.055 | +4.4% | 1.245 | 1.30 | 1.21 | 34,418 | |
| 1.245 | -0.035 | -2.7% | 1.275 | 1.29 | 1.15 | 338,627 | |
| 1.28 | -0.10 | -7.2% | 1.395 | 1.395 | 1.10 | 546,063 | |
| 1.38 | +0.04 | +3.0% | 1.335 | 1.40 | 1.30 | 174,168 | |
| 1.34 | -0.06 | -4.3% | 1.40 | 1.40 | 1.305 | 49,385 | |
| 1.40 | +0.015 | +1.1% | 1.445 | 1.445 | 1.325 | 362,557 | |
| 1.385 | -0.01 | -0.7% | 1.425 | 1.49 | 1.31 | 223,360 |
Splits
1 split · OMXSTO:EXPRS2 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-40 | Consolidation |
- Ticker
- Stockholm:EXPRS2
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Sep 14, 2026
ExpreS2ion Biotech Obtains Commitment for Warrant Program TO 13 and enters into SEK 50 Million Put Option Agreement with lead investor Alumni Capital
Latest earnings call · Aug 20, 2026
ExpreS2ion Biotech Holding (Stockholm:EXPRS2) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
Q3 2026 Earnings Presentation
Earnings · 24 slides
Latest news
ExpreS2ion Biotech Obtains Commitment for Warrant Program TO 13 and enters into SEK 50 Million Put Option Agreement with lead investor Alumni Capital
Sep 14, 2026
Closed 1.33 (+6.0%) on Sep 15, 2026
ExpreS2ion Announces Financial Results for the Second Quarter and First Half of 2026
Aug 20, 2026
Closed 1.39 (-0.7%) on Aug 20, 2026
ExpreS2ion annual report for 2025 published
Jun 4, 2026
Closed 1.63 (+0.9%) on Jun 4, 2026
ExpreS2ion Announces Financial Results for the First Quarter of 2026
May 28, 2026
Closed 1.66 (-0.3%) on May 28, 2026
ExpreS2ion resolves on a set-off issue to one guarantor in connection with completed rights issue
May 11, 2026
Closed 1.98 (+2.9%) on May 12, 2026
ExpreS2ion Biotech: Rights issue outcome – SEK31.8m raised
May 5, 2026
Closed 1.97 (+0.3%) on May 5, 2026
ExpreS2ion announces final outcome of its rights issue of units
May 4, 2026
Closed 1.97 (+0.3%) on May 5, 2026
ExpreS2ion Biotech advances breast cancer project with rights issue of SEK 53 million
Apr 20, 2026
Closed 2.37 (+3.9%) on Apr 20, 2026
ExpreS2ion featured in BioStock investor presentation as subscription period opens in SEK 53 million rights issue
Apr 16, 2026
Closed 2.28 (-2.6%) on Apr 17, 2026
ExpreS2ion publishes prospectus in connection with SEK 53 million rights issue to complete Phase I and support partnering activities
Apr 14, 2026
Closed 3.55 (-27.6%) on Apr 14, 2026
ExpreS2ion Biotech Holding AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 12 in all · newest Sep 14, 2026 · oldest 2026
- Calls
- 10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
- Decks
- 53 decks · latest Nov 12, 2026
Where ExpreS2ion Biotech Holding AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:EXPRS2 · Home listing · This page | Stockholm | Sweden | SEK |
| LS Exchange:A40P4H | LS Exchange | Germany | EUR |
| Lang & Schwarz:A40P4H | Lang & Schwarz | Germany | EUR |
| gettex:5JD0 | gettex | Germany | EUR |
| Stuttgart:5JD0 | Stuttgart | Germany | EUR |
| Frankfurt:5JD0 | Frankfurt | Germany | EUR |
| Munich:5JD0 | Munich | Germany | EUR |
Valuation
EV/sales −6.5× against a median of 42.8×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −24.82M SEK
- P/E
- Loss
- EV/sales
- −6.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- −935.9%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2 | US$794,844 | −US$2.43M | n/a | −6.5× | n/a | 0.2× | −935.9% | 0.0× | n/a |
| SureNano Science Ltd · CSE:SURE | US$1.17M | US$672,321 | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.25 |
| Valion Bio, Inc. · NASDAQ:VBIO | US$1.04M | US$16.34M | n/a | 42.8× | n/a | 0.2× | n/a | 4.1× | 1.11 |
| GeoVax Labs, Inc. · NASDAQ:GOVX | US$985,460 | −US$915,033 | n/a | n/a | n/a | 0.9× | n/a | 0.2× | 1.47 |
| Biodexa Pharmaceuticals plc · NASDAQ:BDRX | US$982,950 | −US$3.22M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.01 |
| Gabather AB · OMXSTO:GABA | US$922,076 | US$560,663 | n/a | n/a | n/a | 6.4× | n/a | 0.0× | n/a |
| Silexion Therapeutics Corp · NASDAQ:SLXN | US$790,001 | −US$3.60M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 2.77 |
| Oragenics Inc. · AMEX:OGEN | US$708,377 | −US$1.12M | n/a | n/a | n/a | 0.7× | n/a | 0.4× | 1.47 |
| Protagenic Therapeutics, Inc. · OTC:PTIX | US$687,879 | US$610,970 | 0.1× | n/a | n/a | 0.6× | n/a | 0.0× | 1.21 |
| Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABT | US$580,337 | −US$2.74M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.46 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Median of the others | US$856,039 | −US$177,185 | 0.1× | 42.8× | 0.3× | 0.0× | 1.21 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 SEK · Analysts' mean
- EPS, year to Dec 2026
- -22.87 · 1 analyst
- Revenue, year to Dec 2026
- 30.4M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Bent U. Frandsen | Chief Executive Officer |
| Keith Alexander | Chief Financial Officer |
| Max M. Søgaard | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Martin Roland Jensen | Chairman |
| Jakob Knudsen | Board Member |
| Karin Garre | Board Member |
| Michel Baijot | Board Member |
Events
- Next results
- Feb 25, 2027 (expected)
Calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 · After close | +3.1% |
| Q2 2026 | Aug 20, 2026 · After close | +1.1% |
| Q1 2026 | May 28, 2026 · After close | 0.0% |
| Q4 2025 | Feb 19, 2026 · After close | −2.1% |
| Q1 2025 | May 15, 2025 · Before open | −3.1% |
| Q4 2024 | Feb 6, 2025 · Before open | −1.3% |
| Q3 2024 | Nov 14, 2024 · Before open | −7.1% |
| Q2 2024 | Aug 15, 2024 · Before open | +4.0% |
| Q1 2024 | May 16, 2024 · Before open | −1.3% |
| Q4 2023 | Feb 8, 2024 · Before open | +0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 16, 2023 · Before open | +17.7% |
| Q2 2023 | Aug 17, 2023 · Before open | −4.1% |
| Q1 2023 | May 16, 2023 · Before open | −2.9% |
| Q4 2022 | Feb 9, 2023 · Before open | +3.0% |
| Q3 2022 | Nov 17, 2022 · Before open | −4.5% |
| Q2 2022 | Aug 18, 2022 · Before open | +1.0% |
| Q1 2022 | May 31, 2022 · Before open | −3.8% |
| Q4 2021 | Feb 24, 2022 · Before open | −13.1% |
| Q3 2021 | Nov 15, 2021 · Before open | +1.3% |
| Quarter to Jun 30, 2021 | Jul 28, 2021 · Before open | +3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 24 slides | Nov 12, 2026 |
| Investor Presentation (October 2026) | Investor deck | 9 slides | Oct 7, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Aug 20, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 21 slides | May 28, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 24 slides | May 28, 2026 |
| BioStock Global Forum 2026 | Conference | 9 slides | May 21, 2026 |
| ØU Life Science Investor Konference 2026 | Conference | 16 slides | Mar 25, 2026 |
| Sachs European Life Science Forum 2026 | Conference | 9 slides | Mar 5, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 18 slides | Feb 19, 2026 |
| Redeye Fight Cancer 2026 | Conference | 18 slides | Jan 21, 2026 |
Show 50 decks
This page holds 50 of 53 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New shares on exercise of TO 13 warrants and directed issue to guarantor Announced: SEK 19.3M–SEK 32.4M · SEK 1.6 a share · Vator Securities +2 Dealers: Vator Securities, SCHMIDT Capital Advisors, APREA Partners Buyers: Vator Securities (guarantee undertaking totalling SEK 19.3 million); Alumni Capital; Tellus Equity AB; Leif Helth Jensen; John Haurum; Thomas Larsson Use of proceeds: Complete the ES2B-C001 Phase I study, strengthen licensing negotiations, platform and CMC development, and business development | Sep 14, 2026 | US$1.98M |
| New shares under put option agreement Announced: up to SEK 50M Buyers: Alumni Capital Limited (commitment of up to SEK 50,000,000 in equity financing over 24 months) | Sep 14, 2026 | US$5.12M |
| Rights offering of units consisting of new shares and warrants of series TO 13 Closed: SEK 31.8M raised · SEK 1.6 a unit · warrants of series TO 13 issued free of charge, exercisable at a price corresponding… · Schmidt Capital Advisors +1 Dealers: Schmidt Capital Advisors, Vator Securities Buyers: Bent U. Frandsen (part of board and management subscription commitments totalling approximately SEK 0.7 million) Insiders: Board members and management, including CEO Bent U. Frandsen, gave subscription commitments totalling approximately SEK 0.7 million, about 1.3 percent of the Rights Issue Use of proceeds: Continue executing the prioritised strategy and support the Company through the period leading up to the TO 13 warrant exercise window | May 4, 2026 | US$3.43M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.66M | 3.01M | 7.05M | 5.09M | 12.2M | 5.26M | 13.8M | 8.87M | 9.79M | 4.65M |
| Cost of revenue | 46.5M | 5.68M | 3.65M | 5.08M | 7.51M | 6.10M | 3.40M | 2.75M | 2.19M | 1.35M |
| Gross profit | -42.8M | -2.67M | 3.40M | 5.00K | 4.72M | -843.0K | 10.4M | 6.12M | 7.60M | 3.30M |
| Research and development | 9.98M | 26.7M | 51.4M | 71.3M | 9.81M | 216.0K | ||||
| Selling, general and administrative | 27.0M | 27.0M | 43.3M | 41.3M | 3.52M | 21.4M | 8.54M | 7.18M | 5.93M | 4.17M |
| Operating income | -52.8M | -67.7M | -106.0M | -127.6M | -48.4M | -31.2M | -16.3M | -18.3M | -11.4M | -9.16M |
| Depreciation and amortization | 1.47M | 1.64M | 1.60M | 1.22M | 1.81M | 2.92M | 2.88M | 2.62M | 2.28M | 1.49M |
| EBITDA | -51.4M | -66.1M | -104.4M | -126.4M | -46.6M | -28.3M | -13.4M | -15.6M | -9.15M | -7.67M |
| Interest expense | 451.0K | 727.0K | 501.0K | 871.0K | 156.0K | 3.53M | 971.0K | 617.0K | 461.0K | 557.0K |
| Income before tax | -44.2M | -44.6M | -100.0M | -126.6M | -47.5M | -34.9M | -19.1M | -18.9M | -11.8M | -9.41M |
| Income tax | -6.09M | -8.53M | -8.57M | -7.98M | -3.59M | -3.21M | -2.38M | -2.03M | -1.92M | -874.0K |
| Net income | -38.1M | -36.0M | -91.4M | -118.6M | -43.9M | -31.7M | -16.7M | -16.8M | -9.84M | -8.54M |
| Earnings per share, basic | -13.39 | -13.88 | -79.22 | -125.71 | -1.36 | -1.66 | -1.03 | -1.14 | -0.81 | -30.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 47.6M | 81.5M | 57.6M | 111.0M | 37.1M | 106.8M | 5.42M | 6.25M | 1.51M | 6.26M |
| Short-term investments | 4.44M | -1.53M | 101.8M | -966.0K | -933.0K | -682.0K | ||||
| Receivables | 9.97M | 5.06M | 2.35M | 10.8M | 7.11M | 5.10M | 4.35M | 4.05M | 4.21M | 5.31M |
| Inventory | -4.05M | -4.21M | 1 | |||||||
| Current assets | 57.5M | 95.0M | 68.7M | 131.9M | 146.5M | 112.5M | 10.1M | 10.8M | 6.05M | 11.8M |
| Property, plant and equipment | 465.0K | 1.53M | 1.77M | 910.0K | 1.21M | 1.29M | 1.19M | 993.0K | 632.0K | 679.0K |
| Goodwill | 0 | 16.0K | 0 | 0 | 194.0K | 802.0K | 1.38M | 1.90M | 2.40M | |
| Total assets | 65.1M | 104.5M | 78.7M | 137.4M | 152.0M | 118.9M | 18.7M | 21.0M | 17.2M | 24.6M |
| Accounts payable | 4.04M | 8.47M | 1.84M | 12.2M | 1.69M | 2.08M | 1.08M | 607.0K | 470.0K | 799.0K |
| Current liabilities | 28.3M | 38.2M | 11.4M | 31.4M | 7.46M | 18.2M | 12.2M | 5.04M | 2.36M | 3.58M |
| Long-term debt | 3.48M | 5.27M | 6.38M | 6.06M | 6.32M | |||||
| Total debt | 2.21M | 1.80M | 1.71M | 1.85M | 5.39M | 7.16M | 7.87M | 6.99M | 6.40M | 5.87M |
| Total liabilities | 29.4M | 40.1M | 13.3M | 34.0M | 11.6M | 24.3M | 19.8M | 12.7M | 10.5M | 11.7M |
| Shareholders' equity | 35.7M | 64.8M | 65.4M | 103.3M | 140.3M | 94.5M | -1.08M | 8.30M | 6.74M | 12.9M |
| Shares outstanding | 2.84M | 2.60M | 1.15M | 943.5K | 32.2M | 19.1M | 16.2M | 14.7M | 12.2M | 283.9K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -40.9M | -33.9M | -100.9M | -99.6M | -45.6M | -18.2M | -12.7M | -12.9M | -8.61M | -7.02M |
| Capital spending | 0 | -870.0K | -2.02M | -383.0K | -715.0K | -885.0K | -679.0K | -813.0K | -206.0K | -720.0K |
| Free cash flow | -40.9M | -34.8M | -102.9M | -100.0M | -46.4M | -19.1M | -13.4M | -13.7M | -8.81M | -7.74M |
| Cash from investing | 0 | 21.3M | -2.02M | 105.3M | -100.9M | -1.08M | -679.0K | -813.0K | -206.0K | -720.0K |
| Cash from financing | 10.8M | 34.9M | 47.8M | 61.5M | 74.5M | 123.4M | 12.6M | 18.6M | 3.98M | 14.7M |
| Share buybacks | 12.1M | 42.3M | 60.7M | 76.0M | 83.3M | 143.2M | 8.00M | 19.3M | -402.0K | -2.11M |
| Change in cash | -34.0M | 23.9M | -53.4M | 73.9M | -69.7M | 101.4M | -837.0K | 4.75M | -4.75M | 5.94M |
Cap table
Built by 6ix from ExpreS2ion Biotech Holding AB’s releases · as of Sep 14, 2026
- Common shares
- 9,883,280
- Fully diluted
- 9,883,280
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 9,883,280 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 9,883,280 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bent U. Frandsen | Chief Executive Officer · Since at least Sep 14, 2026 |
| Jakob Knudsen | Board Member · Since at least Nov 5, 2026 |
| Karin Garre | Board Member · Since at least Nov 5, 2026 |
| Keith Alexander | Chief Financial Officer · Since at least Sep 14, 2026 |
| Martin Roland Jensen | Chairman · Since at least Nov 5, 2026 |
| Max M. Søgaard | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Michel Baijot | Board Member · Since at least Aug 20, 2026 |
Log in to ask 6ix AI your own questions about ExpreS2ion Biotech Holding AB.